BioSpace News Archive

The Public Health Agency of Canada continues to monitor COVID-19 epidemiological indicators to quickly detect, understand and communicate emerging issues of concern.

T2 Biosystems, Inc. a leader in the rapid detection of sepsis-causing pathogens, announced that it issued inducement awards to twenty new employees.

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at ASN Kidney Week 2021 from November 4-7, 2021.

Nabriva Therapeutics plc (NASDAQ: NBRV), today, announced data presentation at CHEST 2021, the annual meeting of the American College of CHEST Physicians, which will be held virtually October 17-20.

Geron Corporation (Nasdaq: GERN) will host a virtual investor event on November 9 at 4:00 p.m. ET. Topics to be covered at the event.

Liminal BioSciences Inc., announced that it has closed on the sale of the remainder of the Company’s plasma-derived therapeutics business under the terms of the previously-announced Share Purchase Agreement entered into by the Company and Kedrion S.p.A..

Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced that the U.S. Food and Drug Administration notified the company that the review of the New Drug Application for FT218 is still ongoing, and action will likely not be taken in October.

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the United States Food and Drug Administration has issued a Complete Response Letter, or CRL, regarding the Biologics License Application for DaxibotulinumtoxinA for Injection, for the treatment of moderate to severe glabellar lines.

TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, announced the appointment of Mark Glickman as the Company’s Chief Business Officer.

XORTX Therapeutics Inc. announced the closing of an underwritten public offering of 2,906,000 units, with each Unit consisting of one common share, no par value, and one warrant to purchase one common share at a public offering price of US$4.13 per Unit, for aggregate gross proceeds of approximately US$12 million, prior to deducting underwriting discounts and other offering expenses.